Relative cost of multidrug-resistant TB medicines in Europe.

Availability and costs of medicines for the treatment of tuberculosis in Europe

OBJECTIVES: To evaluate the access to comprehensive diagnostics and novel antituberculosis medicines in European countries. METHODS: We investigated the access to genotypic and phenotypic Mycobacterium tuberculosis drug susceptibility testing and the …

Rifapentine access in Europe: growing concerns over key tuberculosis treatment component

Beyond multidrug-resistant tuberculosis in Europe: a TBNET study

The emergence of drug-resistant tuberculosis (TB) is a challenge to TB control in Europe. We evaluated second-line drug susceptibility testing in Mycobacterium tuberculosis isolates from patients with multidrug-resistant, pre-extensively …

Multidrug resistant tuberculosis in Europe

Management of patients with MDR-TB in the TBnet clinical network.